Abstract
p73, the homologue of p53, is a nuclear protein whose ectopic expression, in p53+/+ and p53−/− cells, recapitulates the most well-characterized p53 effects, such as growth arrest, apoptosis and differentiation. Unlike p53, which is mutated in half of human cancers, p73 is rarely mutated. However, altered expression of the p73 gene has been reported in neuroblastoma, lung cancer, prostate cancer and renal cell carcinoma. To investigate the potential involvement of p73 in acute myeloid leukemias (AMLs), we analyzed 71 samples from AML patients for the expression pattern of N-terminal transactivation-p73α (TA-p73α), its spliced isoforms and N-terminal-deleted-p73 transcripts (ΔN-p73). We detected p73 gene expression in AML irrespective of FAB (French–American–British) subtypes. Notably, the analysis of ΔN-p73 expression, which has been reported to inactivate both p53 and p73 antitumor effects, revealed a rather peculiar pattern. In fact, ΔN-p73 transcript and protein were detectable in 27/28 (96.4%) cases of M0, M1, M2, M4, M5 and M6 AML and in 13/41 (31.7%) cases of PML-RARα-positive M3 AML (P<0.01). Thus, the distinct gene expression profile of p73 further supports the notion that acute promyelocytic leukemia is a biologically different subset of AML.
Similar content being viewed by others
Introduction
p73, the recently discovered p53 family member, is a nuclear protein that shares a remarkable homology, both at sequence and protein levels, with p53.1 In common with p53, the p73 protein shows three key functional domains: (a) the N-terminal transactivation domain, which shares 29% homology with the N-terminal part of p53; (b) the sequence-specific DNA-binding domain, which shares 63% homology with the corresponding p53 domain and (c) the tetramerization domain, which shares 42% homology with the oligomerization domain of p53.2 The three-dimensional structure of the C-terminal tail of p73 has recently been solved by nuclear magnetic resonance spectroscopy.3 It consists of a five-helix bundle characterized by a marked similarity to the structure of sterile α motif (SAM). These domains are known to be protein–protein interaction modules present in several cytoplasmic signaling proteins and in transcription factors.
Unlike p53, the p73 gene encodes several polypeptides. Two p73 polypeptides were originally identified.1 The longer one, named p73α, comprises 636 amino acids. The shorter one, named p73β, derives from an alternative splicing of exon 13. Additional p73 isoforms that arise from diverse alternative splicings at the C-terminus have recently been identified4, 5, 6, 7, 8 (Figure 1).
Amino-terminally truncated isoforms (ΔN-p73) that lack the transactivation domain and exert dominant-negative function towards p53, p73 and p63 activity have been described9, 10, 11, 12, 13 (Figure 1). These latter isoforms take origin from a cryptic promoter located in the third intron of the p73 gene9 (Figure 1).
Ectopic expression of p73 isoforms in both p53 +/+ and p53−/− recapitulates the well-characterized p53 antitumoral effects, such as growth arrest, apoptosis and differentiation.14, 15, 16 These effects mainly occur through the activation of common and distinct target genes compared to those recruited by wild-type p53.17 Unlike p53, which represents the most frequently mutated gene in human cancers, p73 is rarely mutated.1, 18, 19, 20, 21 Despite its localization in a genomic region frequently altered in neuroblastoma and other cancers, there is still scarce evidence supporting a role of p73 in the pathogenesis of any specific human tumor. As to hematologic neoplasms, no mutations of this gene have been detected in a recent survey including most common myeloproliferative and lymphoproliferative malignancies.21
p73-deficient mice exhibit severe defects, including hydrocephalus, hypocampal dysgenesis, chronic infections and inflammation and abnormalities in the pheromone sensory pathway.9 It has also been reported that p73 mRNA is upregulated during differentiation of muscle, neuronal and hematopoietic cells. Ectopic expression of p73α promotes neuronal and hematopoietic differentiation.16, 22, 23
Here, we have investigated the expression pattern of TAp73α, its spliced isoforms and ΔN-p73 in diagnostic samples derived from patients with acute myelogeneous leukemia (AML), representative of all major morphologic and genetic subsets. We detected p73 expression in all AML types but significantly different ΔN-p73 expression patterns in APL as opposed to other AMLs.
Materials and methods
Patient samples and RNA preparation
Leukemia samples were obtained from peripheral blood or bone marrow specimens collected at diagnosis from 71 AML patients. All patients were diagnosed and treated at the Department of Human Biotechnology and Hematology of the University ‘La Sapienza’ of Rome. Informed consent was obtained from the patients or their parents. The series was representative of the main morphologic subtypes according to the FAB classification system24 and included the following forms: M0 (five samples), M1 (five samples), M2 (five samples), M3 (41 samples), M4 (five samples), M5 (five samples) and M6 (five samples). With concern to genetic characterization, all M3 cases were featured by the presence of the t(15;17) translocation and/or the PML/RARα fusion. Karyotype was available for 28 of 30 non-M3 AML cases. These were subclassified according to the MRC criteria25 as follows: good risk seven cases, intermediate risk 16 cases and poor risk five cases.
A leukemic infiltration >80% was present in all selected samples. Following centrifugation on a Ficoll–Hypaque density gradient, the mononuclear cell fraction was isolated and washed twice in sterile phosphate-buffered saline. Total RNA was extracted from mononuclear cells by the guanidium-isothiocyanate/phenol–chloroform method according to Chomczynsky and Sacchi.26 The quality of RNA was assessed in all cases by agarose gel visualization and amplification of an internal control gene (see below).
All cases were characterized at the genetic level for the presence of major fusion proteins including PML/RARα, AML1-ETO, CBFβ-MYH11 and MLL alterations using standardized methods reported elsewhere.27
Purification and differentiation of hematopoietic progenitor cells (HPC)
HPCs were purified from peripheral blood of healthy donors after informed consent according to the method reported elsewhere.28 Purified HPCs were induced into specific granulopoietic differentiation with interleukin-3 (1 U/ml), granulocyte/monocytes CSF (0.1 ng/ml) and saturating amounts of G-CSF (500 U/ml). Cells were studied at day 14 when they have reached terminal maturation and are fully differentiated.
Normal monocytes were isolated from peripheral blood mononuclear cells by plastic adherence and were used only when >95% cells stained positive for CD14. CD34+ human hemopoietic progenitors cells have been purified from normal cord blood using magnetic beads coated with anti-CD34 antibodies (CD34 Multisort-kit, Miltenyi Biotech GmbH, Bergisch Gladbach, Germany), according to the procedure reported by the manufacturer. At the end of the procedure, purified cells were 97±2% CD34+.
Analysis of the C-terminal p73 isoforms α−ɛ and ΔN-p73 isoform
For the screening of the C-terminal isoforms α–ɛ and for ΔN-p73 isoform, we analyzed total RNA in all cases. RNA (1 μg) was reverse transcribed using random hexamer primers in 20 μl of reaction buffer using MMLV reverse transcriptase and recombinant RNAsin. cDNA (10 μl) were amplified in a total volume of 50 μl of the reaction mixture containing 0.8 mM of each dNTP, 1 × PCR buffer, 1 U of Taq-Gold DNA polymerase (manufactured by Roche) and 10 pmol of each primer. Preheating of the mixture at 94°C for 5 min was followed by 35 cycles of 30 s at 95°C, 2 min at 55°C, 2 min at 72°C. A final extension of 5 min was carried out at 72°C on a Gene Amp PCR system 9700 (Perkin-Elmer, Emeryville, CA, USA). With the aim of simultaneously analyzing the different C-terminal p73 isoforms α−ɛ the following primers, spanning exons 8–14, were used: forward primer, 5′-GACCGAAAAGCTGATGAGGA-3′; and backward primer, 5′-CAGATGGTCATGCGGTACTG-3′.
The following plasmids (pcDNA-HA-α, β, γ, δ, ɛ) were used as templates to detect the length of PCR-amplified fragments corresponding to α–ɛ isoforms. The specificity of the amplified PCR products was confirmed by gel purification and direct sequencing.
Expression of the ΔN-p73 isoform was investigated by nested reverse transcription (RT)-PCR. All cases except two in which no more RNA was available were analyzed. For the first PCR round, 5 μl of cDNA obtained as reported above were amplified in a 50 μl of the reaction mixture containing 0.8 mM of each dNTP, 1 × PCR buffer, 1 U of Taq-Gold DNA polymerase (manufactured by Roche) and 10 pmol of each primer (forward primer, exon 3′: 5′-AAGCGAAAATGCCAACAAAC-3′; backward primer, exon 4: 5′-GGTCCATGGTGCTGCTCAGC-3′). Exon 3′ (Figure 1) is absolutely specific to the ΔN-p73 transcript. Preheating of the mixture at 94°C for 7 min was followed by 30 cycles of 30 s at 95°C, 2 min at 56°C, 2 min at 72°C. A final extension of 5 min was carried out at 72°C on a Gene Amp PCR system 9700. The next PCR was carried out amplifying 10 μl of the first PCR product using the same conditions detailed above, except for the annealing temperature (55°C) and the primers (forward primer: ACTAGCTGCGGAGCCTCTC; backward primer: TGCTCAGCAGATTGAACTGG). The same conditions were used to analyze the isoforms α–ɛ and ΔN-p73 in normal human leukocytes, granulocytes, monocytes, CD34+ progenitors and spleen using a CLONTECH cDNA (CLONTECH Laboratories Inc., Palo Alto, CA 94303-4230, USA). The porphobilinogen deaminase (PBGD) gene served as an internal control for the RT and was amplified from the same cDNA using the following oligonucleotides as primers: forward primer, 5′-CTGGTAACGGCAATGCGGCT-3′; and backward primer, 5′-GCAGATGGCTCCGATGGTGA-3′. PCR products were electrophoresed and visualized on 2% agarose gels stained with ethidium bromide. A schematic representation of the p73 isoforms with the location of the above-described primers used for amplification is shown in Figure 1
ΔN-p73 protein analysis
Whole-cell protein extracts were lysed in lysis buffer (50 mM Tris (pH 6.8), 7% glycerol, 2% SDS, 10 mM DTT, 1mM phenylmethylsulfonyl fluoride and protease inhibitors mixture). The extracts were sonicated for 10 s and centrifuged at 14 000 r.p.m. for 10 min to remove the debris. Protein concentrations were determined by a colorimetric analysis assay (Bio-Rad, Milan, Italy). Total cell lysates (200 μg/lane) were size fractionated on 10% SDS-polyacrylamide gels and blotted into nitrocellulose filters (Bio-Rad). The membranes were blocked in 5% dry milk/TBS-T for 1 h, incubated over night at 4°C with a 1: 1000 dilution of a mixture of anti-p73 monoclonal antibody (Ab-4, NeoMarkers) and visualized using the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Milan, Italy).
Statistical analysis
The analysis was performed using the SAS software. The association between ΔN-p73 expression and other prognostic factors and the differences in the distributions of variable groups of patients were assessed by Kruskal−Wallis, χ2 or the Fisher's exact test.
The probability of disease-free survival was calculated using the Kaplan−Meier method and the prognostic value of potential factors was analyzed using the log-rank test with stratification for risk group.
All analyses were two tailed and were considered statistically significant when P<0.05.
Results and discussion
As shown in Figure 1, our RT-PCR strategy allowed to analyze simultaneously the RNA expression pattern of TA-p73α and related isoforms such as p73β, p73γ, p73δ and p73ɛ in leukemia samples. In agreement with previously reported findings,4, 7, 29, 30 we detected the presence of p73 mRNA transcripts in AML (Figure 2a and b) as compared to the absence in normal human leukocytes, granulocytes, monocytes, CD34+ progenitors and spleen (Figure 2c). This expression was mainly detected for the shorter isoforms and independently from the FAB subtype. No apparent relationship was found between the various short p73 isoforms and karyotypic groups in AML.
It has originally been reported that short p73 isoforms are less efficient than p73α in transactivating gene target promoters and promoting growth suppression and apoptosis.5, 6, 31, 32, 33 However, the molecular mechanisms underlying the reduced transcriptional activity of p73γ, p73δ and p73ɛ are still under investigation. A recent report has shown that the potent transcriptional coactivator Yes-associated protein (YAP) can physically associate with p73α and β but not with p73γ and δ, suggesting that the lack of the recruitment of specific cofactors accounts for the impaired transcriptional activity of alternative spliced isoforms of p73.34, 35 Thus, reduced p73 tumor suppressor activity due to the selective presence of alternative spliced p73 isoforms may potentially contribute to both the transformed phenotype and chemoresistance in leukemic cells.
As to ΔN-p73, its expression pattern was rather heterogeneous in distinct AMLs (Figure 2a and b). In fact, 96.4% of the samples (27 out of 28) representative of different AML FAB subtypes (M0, M1, M2, M4, M5, M6) expressed detectable levels of ΔN-p73 mRNA (Table 1 and Figure 2a and b). After a preliminary analysis on five cases that suggested a distinct expression pattern of ΔN-p73 in M3 subset as compared to other AMLs, the series of M3 samples was expanded to 41 cases. The analysis of these 41 APL (M3) samples showed that only 13 (31.7%) of them expressed ΔN-p73 m-RNA (Figure 3). The APL samples were also analyzed for the expression of the short isoforms at C-terminus. No differences in the expression of p73 short isoforms were detected between ΔN-p73-positive and ΔN-p73-negative APL cases, as well as in the non-APL leukemias (data not shown).
To demonstrate that the ΔN-p73 protein was present in samples from AMLs other than M3, we carried out a Western blot analysis of representative cases. As shown in Figure 4 the ΔN-p73 protein was detectable by a p73 antibody in all the analyzed samples. These findings correlate well with the results of ΔN-p73 mRNA analysis.
ΔN-p73 is a truncated protein that takes origin from a cryptic promoter located in the third intron of the p73 gene and lacks the transcriptional activation domain. Recent studies have clearly shown that ΔN-p73 protein impairs both p53 and p73 transcriptional activity and p53/p73-mediated apoptosis in response to agents inducing DNA damage.10, 11, 12, 13, 36, 37 A rather speculative hypothesis might suggest that lack of the expression of dominant-negative ΔN-p73 protein contributes to the well-known responsiveness of APL to currently adopted treatments, which include anthracycline-based chemotherapy in addition to retinoic acid.38 In line with this hypothesis, it is remarkable that missense mutations of the p53 gene, the most frequent genetic alteration of human cancer that causes the loss of oncosuppressor activities of wild-type p53, have been shown to occur very rarely in APL.39, 40
Recently, it has been shown that the PML gene contains p53-binding sites, which confer responsiveness to p53. Therefore, PML has been proposed as a direct target modulating p53 biological activity.41, 42, 43 The p53/PML crosstalk is likely to be impaired in APL carrying the PML/RARα fusion. It is conceivable to hypothesize that such impairment is balanced by the lack of ΔN-p73 inhibitory effects on p53 activity. p73 upregulation has been observed during myeloid differentiation of the promyelocytic NB4 and the AML-M2 HL-60 cell lines.22, 23, 29 The transcriptional regulation of p73 transcript at the crossroad between proliferation and differentiation has been shown to be regulated by factors that are distinct from those controlling p53 gene expression.17 It has been reported that human tumor-derived p53 mutants can physically associate with and strongly impair the antitumoral effects of the diverse p73 isoforms.31, 44, 45, 46 This interaction involves the specific DNA-binding domain of p73 and the core domain of mutant p53.31, 46 A recent report has shown that in cells carrying mutant p53, the in vivo recruitment of p63 and p73 to the regulatory regions of specific target genes is largely impaired.47
As to the analysis of presenting features and disease outcome according to ΔN-p73 expression, 41 APL patients treated uniformly with retinoic acid and anthracycline chemotherapy were evaluated. As shown in Table 2, no significant differences were detected concerning median age, sex, FAB, median WBC, platelet count and DFS between the two groups of patients positive or negative for ΔN-p73 expression, thus suggesting that ΔN-p73 expression cannot be considered as a prognostic marker.
In conclusion, our study identifies a novel biological feature of APL that further distinguishes this peculiar leukemia subset from other AMLs and may contribute to explain its favorable response to treatment. Additional laboratory studies are needed to elucidate the genetic mechanism underlying the infrequent ΔN-p73 expression in APL and its biologic consequences on cell survival.
References
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809–819.
Arrowsmith CH . Structure and function in the p53 family. Cell Death Differ 1999; 6: 1169–1173.
Chi S-W, Ayed A, Arrowsmith CH . Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J 1999; 18: 4438–4445.
De Laurenzi V, Catani VM, Terrinoni A, Corazzari M, Melino G, Costanzo A et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splice variants epsilon and zeta. Cell Death Differ 1999; 6: 389–390.
Ueda Y, Hijikata M, Takagi S, Chiba T, Shimotohno K . New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 1999; 18: 4993–4998.
De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188: 1763–1768.
Scaruffi P, Casciano I, Masiero L, Basso G, Romani M, Tonini GP . Lack of p73 expression in mature B-ALL and identification of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL. Leukemia 2000; 14: 518–525.
Zaika A, Kovalev S, Marchenko ND, Moll UM . Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999; 59: 3257–3263.
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin C et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99–103.
Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M . p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 2002; 18: 4715–4727.
Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F et al. Human deltaNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8: 1213–1223.
Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196: 765–780.
Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H et al. Autoinhibitory regulation of p73 by DeltaNp73 to modulate cell survival and death through a p73-specific target element within the DeltaNp73 promoter. Mol Cell Biol 2002; 22: 2575–2585.
Jost CA, Marin MC, Kaelin WG . p73 is a human p53 related protein that can induce apoptosis. Nature 1997; 389: 191–194.
Stiewe T, Pulzer BM . Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002; 9: 237–243.
De Laurenzi V, Raschellà G, Barcaroli D, Annichiarico-Petruzzelli M, Ranalli M, Catani MV et al. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem 2000; 275: 15226–15231.
Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002; 277: 43359–43368.
Kaelin J . The p53 family. Oncogene 1999; 18: 7701–7705.
Kong XT, Valentine VA, Rowe ST, Valentine MB, Ragsdale ST, Jones BG et al. Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia 1999; 1: 80–89.
Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM . Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998; 9: 897–903.
Stirewalt DL, Clurman B, Appelbaum FR, Willman CL, Radich JP . P73 mutations and expression in adult de novo acute myelogenous leukemia. Leukemia 1999; 13: 985–990.
Morena AR, Riccioni S, Marchetti A, Tartaglia Polcini A, Mercurio AM, Blandino G et al. Expression of β4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. Blood 2002; 100: 96–106.
Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G et al. The transcriptional repressor ZEB regulates p73 expression at the cross-road between proliferation and differentiation. Mol Cell Biol 2001; 24: 8461–8470.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med 1985; 103: 620–625.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.
Chomczynski P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate−phenol chloroform extraction. Anal Biochem 1987; 162: 156–159.
Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Gabbianelli M, Sargiacomo M, Pelosi E, Testa U, Isacchi G, Peschle C . ‘Pure’ human hematopoietic progenitors: permissive action of basic fibroblast growth factor. Science 1990; 249: 1561–1564.
Tschan MP, Grob TJ, Peters UR, De Laurenzi V, Huegli B, Kreuzer KA et al. Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophy Res Commun 2000; 277: 62–65.
Peters UR, Tschan MP, Krenzer KA, Baskaynak G, Lass U, Tobler A et al. Distinct expression patterns of the p53-Homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res 1999; 59: 4233–4236.
Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275: 29503–29512.
Levrero M, De Laurenzi V, Costanzo A, Sabatini S, Gong J, Wang JYJ et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113: 1661–1670.
Takagi S, Ueda Y, Hijikata M, Shimonoto K . Overproduced p73α activates a minimal promoter through a mechanism independent of its transcriptional activity. FEBS Lett 2001; 509: 47–52.
Strano S, Munarriz E, Rossi M, Cristofanelli B, Castagnoli L, Shaul Y et al. Physical interaction with Yes-associated protein (YAP) enhances p73 transcriptional activity. J Biol Chem 2001; 276: 15164–15173.
Basu S, Totty NF, Irwin MS, Sudol M, Downward J . Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11–23.
Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 21: 3796–3803.
Petrenko O, Zaika A, Moll UM . deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003; 23: 5540–5555.
Tallman MS, Nabhan CH, Feusner JH, Rowe JM . Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
Longo L, Trecca D, Biondi A, Lo Coco F, Grignani F, Maiolo AT et al. Frequency of RAS and p53 mutations in acute promyelocytic leukemias. Leukemia Lymphoma 1993; 11: 405–410.
Trecca D, Longo L, Biondi A, Cro L, Calori R, Grignani F et al. Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 1994; 46: 304–309.
Gostissa M, Hofmann TG, Will H, Del Sal G . Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol 2003; 15: 351–357.
Hodges M, Tissot C, Howe K, Grimwade D, Freemont PS . Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet 1998; 63: 297–304.
De Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 2004; 13: 523–535.
Di Como CJ, Gaiddon C, Prives C . p73 Function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438–1449.
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 47–54.
Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C . A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874–1887.
Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. Physical interaction with human tumor derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817–18826.
Acknowledgements
We are grateful to William Kaelin Jr, Makoto Hijikata, Massimo Romani and Franco Mandelli for plasmids and helpful suggestions. We thank Sabrina Riccioni for technical assistance. This work has been supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Ministero della Salute-Italy, CNR-Italy, Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) and European Community.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rizzo, M., Giombini, E., Diverio, D. et al. Analysis of p73 expression pattern in acute myeloid leukemias: lack of ΔN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 18, 1804–1809 (2004). https://doi.org/10.1038/sj.leu.2403483
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403483
Keywords
This article is cited by
-
Clinical implications of the deregulated TP73 isoforms expression in cancer
Clinical and Translational Oncology (2018)
-
A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome
Cell Death & Disease (2018)
-
miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia
Oncogene (2013)
-
Functions, divergence and clinical value of TAp73 isoforms in cancer
Cancer and Metastasis Reviews (2013)
-
ΔN-p73 is a transcriptional target of the PML/RARα oncogene in myeloid differentiation
Cell Death & Differentiation (2007)